SAB Biotherapeutics signs $20M ATM equity offering with Cantor Fitzgerald

SAB Biotherapeutics, Inc.

ATM agreement allows sale of up to $20M of common stock through Cantor as sales agent.
Agent will receive 3.0% of gross proceeds per sale; no minimum obligation to sell.
Net proceeds to fund pipeline development and general corporate/working capital.
Agreement is terminable by either party on ten days' notice.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

SAB Biotherapeutics, Inc. entered into Controlled Equity OfferingSM Sales Agreement with Cantor Fitzgerald & Co. valued at $20,000,000 (effective 2024-01-26).

Action: entry
Agreement: atm program
Counterparty: Cantor Fitzgerald & Co.
Value: $20,000,000
Effective: 2024-01-26

Exact text from the filing

On January 26, 2024, SAB Biotherapeutics, Inc. (the “Company”) entered into a Controlled Equity OfferingSM Sales Agreement (the “Agreement”) with Cantor Fitzgerald & Co. (the “Agent”). In accordance with the terms of the Agreement, pursuant to the Prospectus Supplement (as defined below), the Company may offer and sell from time to time through or to the Agent, as sales agent, the Company’s common stock, par value $0.0001 per share, having an aggregate offering price of up to $20,000,000 (the “Placement Shares”).

View on SEC.gov

Browse all material agreements →

SAB Biotherapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-007941

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.